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Background: This study aimed to evaluate the gene expression of cyclooxygenases (COXs) in an oral model of 
preemptive analgesia. 
Material and Methods: Gingival tissue was collected during extraction of lower third molars from a randomized, 
triple-blind, split-mouth and placebo-controlled study. The eligible patients were randomly sorted to receive a 
single dose either of ibuprofen 400mg, or etoricoxib 120 mg or a placebo, one hour prior to surgery. The temporal 
course of RNAm was evaluated for COX-1 and -2 by means of a quantitative polymerase chain reaction in real 
time (RT-qPCR) at time zero and 30 minutes after the surgical procedure began, and it was correlated with clinical 
parameters (pain and maximum mouth opening). 
Results: There was a significant increase in COX-1 expression between T0 and T30 in ibuprofen (p=0.004) and eto-
ricoxib (p=0.010) groups. As regards COX-2, there were increases from T0 to T30 in all groups (placebo, p=0.012; 
ibuprofen, p<0.001; etoricoxib, p<0.001). All groups showed a significant decrease in COX-2:COX-1 ratio from 
T0 to T30 (placebo, p=0.013; ibuprofen, p<0.001; etoricoxib, p=0.047). Experimental groups showed a significant 
correlation between COX-1 and COX-2 levels and clinical pain parameters. 
Conclusions: The present preemptive analgesia study concludes that COX-2 RNAm induction was directly linked 
to third molar-related tissue inflammation and that the relation between COX-1 and COX-2 levels were inversely 
proportional to the preemptively administered nonsteroidal anti-inflammatory drugs COX-2 selectivity. 
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Introduction
Cyclooxygenase (COX) catalyzes the initial steps in the 
synthesis of prostaglandins (PGs) and other eicosanoids 
from arachidonic acid. PGE2, one of the many arachi-
donic acid metabolites derived from COX, is released 
in inflamed tissues, sensitizing afferent nerve fibers, and 
increasing nociception to evoke a hyperalgesic state 
(1). COX-1 and -2 are derived from different genes and 
constitute the main targets of non-steroidal anti-inflam-
matory drugs (NSAIDs). The messenger RNA (mRNA) 
originated from COX-1 expression presents a half-life of 
approximately 12-15 hours, whereas COX-2 gives rise 
to mRNA with a shorter half-life of less than 3.5 hours 
(2). These findings suggest an intrinsic temporal connec-
tion between tissue injury, COX-2 expression and the 
observed increase in PGE2 levels during inflammation. 
This connection is not observed in association with the 
constitutively expressed COX-1. COX inhibition provi-
ded by NSAIDs confers relief of pain and inflammation 
that follows oral surgery procedures, justifying clinical 
interest on COX isoforms (3). 
Third molar surgeries are highly invasive procedures ca-
pable of triggering various levels of inflammatory pain 
that may potentially impact the quality of life of patients 
with short and medium-term repercussions; hence, these 
procedures have been historically established models to 
study the efficacy of various centrally and non-centra-
lly acting analgesics and anti-inflammatory drugs (4-6). 
A previous study demonstrated a distinct synthesis of 
COX-1 metabolites and PGE2 production mediated by 
COX-1 and -2 following oral surgery procedures, in the 
absence of rescue medications (7).
Preemptive analgesia aims to prevent or diminish posto-
perative pain and inflammation, reducing the need for me-
dication in the days immediately following surgery (3,8). 
Studies have demonstrated etoricoxib’s efficacy as a se-
lective COX-2 inhibitor with few gastro-intestinal effects 
when used to treat acute pain associated with oral-dental 
surgery (3), and 120 mg was described as the minimum 
dose of etoricoxib that demonstrates maximum analgesic 
effect (9). In addition, ibuprofen is one of the most com-
monly used drug to control dental pain, and its efficacy in 
treating pain associated with dental surgery in the posto-
perative period has been widely demonstrated (8,10). 
The primary objective in this study was to evaluate the 
association between COX-1 and COX-2 RNAm induc-
tion and clinical inflammatory parameters (pain scores, 
rescue medication intake, and maximum mouth opening) 
in third molar surgeries. This objective was based on the 
study hypothesis that the inflammatory process related 
to these surgical procedures is associated with COX-1 
and COX-2 RNAm induction. In addition, the secondary 
objective in this investigation was to assess the levels of 
COX-1 and COX-2 RNAm according to the preempti-
vely administered NSAID in third molars surgeries. This 
objective was formulated to test the hypothesis that the 
NSAID type used before the surgical procedure may in-
fluence the COX gene isoforms expression in gingival 
tissue collected from patients exposed to the preemptive 
administration of placebo, ibuprofen, and etoricoxib.
Material and Methods
-Study Design and Sample size calculation
This study had an analytical design. Gingival tissue was 
collected during extraction of impacted lower third mo-
lars from patients, during the course of a previous clini-
cal trial that had a randomized, triple-blind, split-mouth 
and placebo-controlled study design (11). The following 
inclusion criteria were adopted to standardize the level 
of traumatic injury generated by surgery: patients with 
third molars requiring ostectomy, with or without asso-
ciated tooth sectioning; patients with third molars that 
showed similar patterns of root formation, position, and 
degree of impaction. In addition, the following exclu-
sion criteria were adopted: smokers, pregnant or breast 
feeding, users of medications that could interact with the 
drugs used in this study, patients with orthodontic bands 
on the mandibular second molars, confirmed history of 
allergy to NSAIDs, signs of any preoperative inflam-
matory or infectious condition, systemic chronic disea-
se, use of NSAIDs within the past 21 days, or the pre-
sence of periodontal disease, swelling, fever, or trismus 
prior to surgery (11). The previous study was approved 
by the Ethics Committee of the Walter Cantídio Univer-
sity Hospital (WCUH) No. 44058715.4.0000.5045.
During that study, patients donated tissue for the present 
investigation by signing an informed consent form. Pa-
tients had been subjected to preemptive analgesia by ta-
king ibuprofen 400mg, or etoricoxib 120mg or a place-
bo with no active pharmaceutical principal. In addition, 
the previously recorded pain scores by using the visual 
analog scale (VAS) at 0, 2, 4, 6, 8, 10 and 12 hours, and 
1, 5 and 7 days postoperatively, rescue medication in-
take, maximum mouth opening (at baseline and 7 days 
postoperatively), and the surgical period duration were 
evaluated in the present research.
A previous study (3) observed VAS of 2.7±1.6 and 
0.2±0.1 for two different groups preemptively treated 
with placebo and etoricoxib, respectively. The data 
obtained established that a minimum sample size of 5 
surgical sites per group yields a power of 90%, and al-
pha=0.05 in order to accept or reject the null hypotheses. 
To obtain the minimum sample size per group from the 
original study carried out by Albuquerque et al. (11) a 
second randomization was performed using a method to 
generate the random allocation sequence (“randomiza-
tion per block” function of the Microsoft Excel®).
-Sample acquisition and Study of the time-course of 
COX-1 and COX-2 mRNA expressions
This study sample consisted of 30 fragments of pericoro-
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nal tissue evenly distributed according to treatment recei-
ved (ibuprofen, n=10; etoricoxib, n=10; placebo, n=10), 
and time of collection per group (T0, n=5 per group and 
T30, n=5 per group). Gingival fragments of pericoronal 
tissue (close to the tooth being removed) were collected 
in two separate moments (T0= at the beginning of surgery 
and T30= 30 minutes later). Samples were identified by 
a number so that the investigator would not know which 
group gingival samples belonged to.
To study the time-course of the COX-1 and COX-2 gene 
expression, the primers were designed on the basis of 
data obtained from the NCBI gene bank using the Pri-
merBlast program with exclusive specificity for Homo 
sapiens. GAPDH was used as the endogenous control 
(housekeeping) gene because it is a gene that is not affec-
ted by the inflammatory condition that is being analyzed 
in the present study and also to normalize samples for 
possible differences in cDNA quantities added in each 
reaction. The primers used for the target genes (COX-
1 and COX-2) were developed by exon-exon ligating, 
thereby making genomic DNA amplification unfeasible.
-Spectrophotometric Quantification  
To test the efficacy of extraction and total RNA purity 
the concentration of total RNA in the samples was deter-
mined by RNA dilution (known dilution factor) together 
with a spectrophotometric reading in quartz cuvettes, 
using wavelengths of de 260 nm (A260) and 260/280 nm 
(A260/A280). 
-RNA extraction and cDNA synthesis
Isolation of total RNA was performed using the Pure-
Link® RNA Mini Kit (Life Technologies, New York, 
USA). The RNA concentration was estimated by reading 
the absorbance at 260 nm and was checked for purity at 
280 nm in a spectrophotometer (Amersham Biosciences, 
Cambridge, England). For each sample, RNA concentra-
tions were adjusted and used to synthesize cDNA with 1 
µL. Before the reverse transcription reaction, samples of 
RNA were incubated for 5 min at 70 ºC and then cooled 
in ice. The reverse transcription was performed in a total 
volume of 20 µL composed of 10 µL of sample RNA, 4 
µL reverse transcriptase buffer (Invitrogen, São Paulo, 
Brazil), 8 units RNase out, 150 units of reverse trans-
criptase Superscript III, 0036 U random primers, 10 mM 
DTT and 0.5mM of each dNTP (Invitrogen, São Paulo, 
Brazil). The mixture was incubated at 42 ºC for 1 h, sub-
sequently at 80 ºC for 5 min, and finally stored at –20 ºC. 
The negative control was prepared under the same con-
ditions, but without the addition of reverse transcriptase.
-Quantitative reverse transcription (qRT)-PCR evalua-
tion
Quantification of mRNA was performed using SYBR 
GreenMaster Mix (PE Applied Biosystems, Foster City, 
CA). PCR reactions were composed of 1 μL cDNA 
as a template in 7.5 μL of GoTaq® qPCR Master Mix 
(Promega Corporation, Madison, WI, USA), 5.5 µL of 
ultra-pure water, and 0.5 μM of each primer. The pri-
mers were designed by using the PrimerQuestSM pro-
gram (http://www.idtdna.com), and GAPDH was used 
as the normalizing gene. The specificity of each primer 
pair was confirmed by melting curve analysis of PCR 
products. The thermal cycling profile for the first round 
of PCR was: initial denaturation and activation of the 
polymerase for 10 min at 95 oC, followed by 40 cycles 
of 15 sec at 95 ºC, 30 sec at 58 ºC, and 30 sec at 72 ºC. 
The final extension was for 10 min at 72 ºC. All reac-
tions were performed in StepOne Real-Time PCR, and 
relative quantifications of mRNA used the comparative 
threshold cycle (Ct) (Ct) method.
-Statistical Analysis
Data were expressed in mean and standard error of the 
mean for comparison with pared t-test or ANOVA (1-
way or 2-way) followed by Bonferroni post hoc test. 
Chi-square and Fisher Exact tests were used to evaluate 
associations between categorical variables (n, %) (Gra-
phPad Prism 5.0, p<0.05). Pearson correlation was used 
in order to correlate COX-1 and COX-2 levels with cli-
nical parameters.
Results
-Sample characterization and mRNA expression of 
COX-1 and COX-2
The average age of the patients was 22 years. Patients 
did not differ regarding demographic or surgical factors, 
such as the eventual extraction difficulties, dental posi-
tion, or quantity of anesthetic used (Table 1). RT-PCR 
showed no difference in COX-1 expression in the place-
bo group from T0 to T30; however, in the groups trea-
ted with ibuprofen (p=0.004) and etoricoxib (p=0.010) 
showed a significant increase in the COX-1 expression 
from the first (T0) to the second moment (T30) (Fig. 
1A). The increase in the COX-1 expression was sig-
nificantly greater in the groups treated with ibuprofen 
(0.9±0.3) and etoricoxib (1.1±0.2) than in the placebo 
group (0.1±0.2) (p=0.020).
All three groups showed an increase in COX-2 ex-
pression from T0 to T30 (placebo, p=0.012; ibupro-
fen, p<0.001; etoricoxib, p<0.001) (Fig. 1B). Only the 
group treated with etoricoxib showed a modest increase 
in COX-2 expression compared to the placebo group 
(p=0.023); however, there was no difference between 
the placebo group and the group treated with ibuprofen 
(Fig. 2). The three groups showed a significant reduction 
in the ratio of COX-2 to COX-1 expressions from T0 to 
T30 (placebo, p=0.013; ibuprofen, p<0.001; etoricoxib, 
v=0.047). 
-Relationship between COX-1 and COX-2 expressions 
and clinical parameters
Clinically, pain scores of the ibuprofen group were signi-
ficantly lower than the placebo group from 8h to 24h after 
the surgical procedure (p<0.001). The pain scores of the 
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Groups
Placebo Ibuprofen Etoricoxib p-Value
Gender
Male 0 (0%) 2 (40%) 2 (40%) 0.256
Female 5 (100%) 3 (60%) 3 (60%)
Age (years)
≤20 0 (0%) 2 (40%) 0 (0%) 0.136
21-30 3 (60%) 1 (20%) 4 (80%)
31-40 2 (40%) 2 (40%) 0 (0%)
>40 0 (0%) 0 (0%) 1 (20%)
Degree of tooth eruption
Total bone inclusion 0 (0%) 1 (20%) 1 (20%) 0.525
Partial bone inclusion 3 (60%) 3 (60%) 4 (80%)
Erupted partially 2 (40%) 1 (20%) 0 (0%)
Relation with mandibular ramus
Class I 3 (60%) 1 (20%) 2 (40%) 0.406
Class II 2 (40%) 4 (80%) 2 (40%)
Class III 0 (0%) 0 (0%) 1 (20%)
Relation with second molar
Position A 1 (20%) 1 (20%) 0 (0%) 0.558
Position B 4 (80%) 4 (80%) 4 (80%)
Position C 0 (0%) 0 (0%) 1 (20%)
Relation with inferior alveolar canal
Interruption of the radiopaque line 1 (20%) 0 (0%) 1 (20%) 0.167
Darkening of the third molar root 0 (0%) 2 (40%) 0 (0%)
Deflection of the root 0 (0%) 2 (40%) 0 (0%)
Absent 3 (60%) 1 (20%) 3 (60%)
Interruption of the radiopaque line + darkening 
of the third molar root
0 (0%) 0 (0%) 1 (20%)
Interruption of the radiopaque line + deflection 
of the root 
1 (20%) 0 (0%) 0 (0%)
Surgery period (minutes)
≤10 0 (0%) 0 (0%) 1 (20%) 0.558
11-15 4 (80%) 4 (80%) 4 (80%)
>15 1 (20%) 1 (20%) 0 (0%)
Tooth sectioning during surgery
Yes 3 (60%) 3 (60%) 2 (40%) 0.765
No 2 (40%) 2 (40%) 3 (60%)
Tooth position 0.741
Vertical 1 (20%) 2 (40%) 2 (40%)
Mesioangular 4 (80%) 3 (60%) 3 (60%)
Table 1: Sample characterization.
*p<0.05, Chi-square or Fisher exact tests.
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Fig. 1: COX-1 and COX-2 tissue level between the studied groups at 0 and 30 minutes after the surgical procedure. *p<0.05 
in relation to the experimental period 0 minutes of the same group (paired t-test).
Fig. 2: Variation of the COX-1 and COX-2 tissue level between the studied groups after the surgical procedure. *p<0.05 in relation 
to the experimental groups versus the placebo group (one-way ANOVA test).
etoricoxib group were significantly lower in comparison 
with the placebo group from 4h to 24h after the surgical 
procedure (p<0.001), and pain scores of the etoricoxib 
group were significantly lower in comparison with the ibu-
profen group 4h after the surgical procedure (p=0.047). The 
area under the postoperative pain experience curve of the 
placebo group (31.2) was 2.6 times higher than the ibupro-
fen group (11.8) and 5.2 times higher than the etoricoxib 
group (6) (Fig. 3). In relation to the maximum mouth ope-
ning 7 days after surgery, there was a statistical differen-
ce (p=0.001) between placebo (11.5±1.9 mm), ibuprofen 
(4.4±0.7 mm), and etoricoxib (2.4±0.6 mm) groups.
Fig. 3: Graphical representation of the pain scores over the studied periods. The area under 
the curve shows pain experience significantly reduced in etoricoxib (p<0.0001) and ibupro-
fen (p=0.006) groups in comparison with placebo, and significantly reduced in etoricoxib 
group in comparison with ibuprofen group (p = 0.0488). P, placebo; two-way ANOVA test. 
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According to Tables 2-4, group treated with ibuprofen 
showed an inverse correlation between COX-1 level at 
T0 and pain peak after 4h (p=0.034, r= -0.905), between 
COX-1 level at T30 and baseline mouth opening (p= 
0.044, r = -0.889) and after 7 days (p = 0.013, r = -0.915). 
There was also a significant inverse correlation between 
COX-2 level at T0 and pain peak after 10h (p=0.001, r = 
-0.990) and 12h (p=0.001, r = -0.990), and T30 and pain 
peak after 24h (p=0.001, r = -0.993). In addition, COX-
2 level and the consumption of rescue medication were 
  COX-1 COX-2
T0 T30 T30-T0 T0 T30 T30-T0
Placebo  
Surgery period r -0.240 0.107 0.426 0.605 0.121 -0.388
 p-Value 0.698 0.864 0.474 0.280 0.847 0.519
Maximum mouth 
openning (baseline)
r -0.463 -0.427 0.423 -0.552 -0.833 -0.137
 p-Value 0.433 0.473 0.478 0.334 0.080 0.826
Maximum mouth 
openning (7 days)
r 0.261 -0.109 -0.460 -0.578 -0.099 0.381
 p-Value 0.671 0.862 0.436 0.308 0.874 0.526
Maximum mouth 
openning (Δ)
r 0.561 0.101 -0.777 -0.391 0.330 0.529
 p-Value 0.325 0.872 0.122 0.515 0.587 0.359
Rescue medication 
intake
r -0.483 0.037 0.757 0.406 -0.700 -0.792
 p-Value 0.409 0.953 0.138 0.497 0.188 0.110
VAS 0h r 0.000 0.000 0.000 0.000 0.000 0.000
 p-Value 1.000 1.000 1.000 1.000 1.000 1.000
VAS 2h r -0.252 0.239 0.547 0.374 -0.775 -0.818
 p-Value 0.683 0.698 0.340 0.535 0.123 0.090
VAS 4h r 0.535 0.873 -0.217 0.820 -0.362 -0.884
 p-Value 0.353 0.053 0.726 0.089 0.549 0,094
VAS 6h r -0.071 0.432 0.402 0.569 -0.711 -0.926
 p-Value 0.910 0.468 0.502 0.317 0.178 0.052
    VAS 8h r -0.336 0.178 0.632 0.395 -0.771 -0.832
 p-Value 0.581 0.774 0.253 0.510 0.127 0.081
VAS 10h r -0.574 -0.127 0.788 0.148 -0.905 -0.731
 p-Value 0.311 0.839 0.114 0.812 0.070 0.161
VAS 12h r -0.522 -0.255 0.621 -0.212 -0.453 -0.143
 p-Value 0.367 0.679 0.264 0.732 0.443 0.818
VAS 24h r -0.315 -0.147 0.379 -0.191 -0.159 0.040
 p-Value 0.605 0.813 0.529 0.758 0.798 0.949
VAS 5d r -0.558 -0.089 0.788 0.135 -0.787 -0.641
 p-Value 0.329 0.887 0.114 0.828 0.114 0.244
VAS 7d r -0.252 0.239 0.547 0.374 -0.775 -0.818
 p-Value 0.683 0.698 0.340 0.535 0.123 0.090
Table 2: Pearson correlation between COX-1 and COX-2 gene expressions and clinical parameters (placebo group).
*p<0,05, correlação de Pearson; VAS, visual analogue scale.
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  COX-1 COX-2
T0 T30 T30-T0 T0 T30 T30-T0
Ibuprofen  
Surgery period r -0.191 0.634 0.608 0.496 0.293 -0.212
 p-Valor 0.758 0.250 0.276 0.396 0.632 0.733
Maximum mouth 
openning (baseline)
r -0.049 -0.889* -0.694 -0.493 0.054 0.633
 p-Valor 0.938 0.044 0.194 0.399 0.931 0.252
Maximum mouth 
openning (7 days)
r -0.012 -0.951* -0.762 -0.569 -0.030 0.608
 p-Valor 0.984 0.013 0.134 0.317 0.962 0.277
Maximum mouth 
openning (Δ)
r 0.143 -0.213 -0.244 -0.278 -0.328 -0.118
 p-Valor 0.819 0.730 0.693 0.651 0.590 0.850
Rescue medication intake r -0.468 0.716 0.813 0.990* 0.875 0.403
 p-Valor 0.426 0.173 0.094 0.001 0.052 0.501
VAS 0h r 0.000 0.000 0.000 0.000 0.000 0.000
 p-Valor 1.000 1.000 1.000 1.000 1.000 1.000
VAS 2h r -0.206 0.001 0.104 -0.280 -0.253 -0.437
 p-Valor 0.740 0.998 0.867 0.648 0.681 0.462
VAS 4h r -0.905* -0.219 0.277 0.192 0.618 0.596
 p-Valor 0.034 0.724 0.651 0.757 0.267 0.289
VAS 6h r -0.609 -0.306 0.058 -0.427 -0.178 -0.220
 p-Valor 0.275 0.617 0.926 0.473 0.775 0.722
VAS 8h r 0.240 -0.359 -0.410 -0.769 -0.843 -0.644
 p-Valor 0.697 0.553 0.492 0.129 0.073 0.240
VAS 10h r 0.468 -0.716 -0.813 -0.990* -0.875 -0.403
 p-Valor 0.426 0.173 0.094 0.001 0.052 0.501
VAS 12h r 0.468 -0.716 -0.813 -0.990* -0.875 -0.403
 p-Valor 0.426 0.173 0.094 0.001 0.052 0.501
VAS 24h r 0.616 -0.427 -0.654 -0.875 -0.993* -0.677
 p-Valor 0.269 0.473 0.231 0.052 0.001 0.210
VAS 5d r 0.000 0.000 0.000 0.000 0.000 0.000
 p-Valor 1.000 1.000 1.000 1.000 1.000 1.000
VAS 7d r 0.000 0.000 0.000 0.000 0.000 0.000
 p-Valor 1.000 1.000 1.000 1.000 1.000 1.000
Table 3: Pearson correlation between COX-1 and COX-2 gene expression and clinical parameters (ibuprofen group). 
*p<0,05, correlação de Pearson; VAS, visual analogue scale.
directly correlated (p=0.001, r = 0.990). In the group 
treated with etoricoxib, there was a significant inverse 
correlation between COX-1 level at T0 and pain peak 
after 2h (p=0.015, r = -0.947), as well as direct correla-
tion between COX-1 and pain peak after 6h (p=0.032, r 
= 0.910). COX-2 level showed a significant direct corre-
lation with pain peak after 24h in both T0 (p=0.006, r = 
0.969) and T30 (p=0.027, r = 0.919) evaluated periods.
Discussion
Third molar surgery was selected to validate the clinical 
model used in the research because it has been widely 
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  COX-1 COX-2
T0 T30 Δ T0 T30 Δ
Etoricoxib  
Surgery period r 0.797 0.377 -0.707 0.212 0.179 -0.461
 p-Valor 0.106 0.532 0.182 0.732 0.773 0.434
Maximum mouth openning 
(baseline)
r -0.452 -0.361 0.335 0.683 0.798 0.053
 p-Valor 0.445 0.551 0.582 0.203 0.106 0.932
Maximum mouth openning 
(7 days)
r -0.397 -0.278 0.316 0.710 0.807 0.010
 p-Valor 0.508 0.650 0.604 0.179 0.099 0.988
Maximum mouth openning 
(Δ)
r 0.690 0.780 -0.380 -0.392 -0.590 -0.301
 p-Valor 0.197 0.120 0.527 0.514 0.295 0.623
Rescue medication intake r 0.639 0.709 -0.344 0.502 0.299 -0.113
 p-Valor 0.246 0.180 0.570 0.389 0.625 0.856
VAS 0h r 0.000 0.000 0.000 0.000 0.000 0.000
 p-Valor 1.000 1.000 1.000 1.000 1.000 1.000
VAS 2h r -0.947* -0.732 0.693 0.037 0.197 0.405
 p-Valor 0.015 0.160 0.195 0.953 0.751 0.499
VAS 4h r -0.525 -0.441 0.377 0.619 0.604 0.841
 p-Valor 0.364 0.457 0.531 0.266 0.281 0.075
VAS 6h r -0.767 0.073 0.910* -0.013 0.044 -0.385
 p-Valor 0.130 0.907 0.032 0.984 0.944 0.522
VAS 8h r -0.865 -0.651 0.636 -0.265 -0.067 0.062
 p-Valor 0.059 0.234 0.249 0.666 0.914 0.921
VAS 10h r -0.797 -0.377 0.707 -0.212 -0.179 0.461
 p-Valor 0.106 0.532 0.182 0.732 0.773 0.434
VAS 12h r -0.797 -0.377 0.707 -0.212 -0.179 0.461
 p-Valor 0.106 0.532 0.182 0.732 0.773 0.434
VAS 24h r 0.155 -0.163 -0.245 0.969* 0.919* 0.568
 p-Valor 0.804 0.794 0.692 0.006 0.027 0.318
VAS 5d r 0.000 0.000 0.000 0.000 0.000 0.000
 p-Valor 1.000 1.000 1.000 1.000 1.000 1.000
VAS 7d r 0.000 0.000 0.000 0.000 0.000 0.000
 p-Valor 1.000 1.000 1.000 1.000 1.000 1.000
Table 4: Pearson correlation between COX-1 and COX-2 gene expression and clinical parameters (etoricoxib group).
*p<0,05, correlação de Pearson; VAS, visual analogue scale.
practiced and validated in pharmacological trials sin-
ce 1976 by Cooper and Beaver (12), as well as being a 
common dental procedure in which postoperative pain 
is usually short-lasting reaching its height in the initial 
stage immediately after the surgical trauma affecting the 
surrounding tissues (13). That model has been conside-
red highly important in clinical investigations to distin-
guish the analgesic effects of various drugs, as was the 
case in the present research, or to investigate the effects 
of different dosages of a single drug (14,15). 
This study investigated the effect of preemptive oral 
administration of ibuprofen and etoricoxib on COX-1 
and COX-2 levels in gingival tissue. These two drugs 
are commonly administered in lower third molar remo-
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val procedures as a means of controlling postoperative 
pain. In fact, the area under the curve, correlating the 
pain scores over the time, showed that both experimen-
tal groups reduced the pain scores in comparison with 
the placebo group, and the etoricoxib was the drug who 
significantly reduced the pain scores. Cyclooxygenase, 
also known as prostaglandin H synthase is the key enzy-
me in prostaglandin synthesis. The original elucidation 
of the two COX isoforms gave rise to the concept that 
the constitutive enzyme COX-1 was responsible for the 
production of prostaglandins with homeostatic functions 
in stomach and kidney tissues and in platelet aggrega-
tion, whereas COX-2 is induced and responsible for the 
production of pro-inflammatory substances, especially 
PGE2 (16). The contribution of COX-2 to inflammation 
is further supported by the fact that COX-2 expression 
can become from ten to 80 times greater in the presence 
of pro-inflammatory cytokines such as IL-6, IL-1, and 
prostaglandin production can be inhibited by anti-in-
flammatory cytokines (17). However, most studies have 
focused on measuring tissue cytokine levels instead 
of evaluating the impact of the use of COX-2 selecti-
ve NSAIDs on tissue levels of these enzymes.  To our 
knowledge this is the first investigation evaluating gene 
expression of COXs in human tissues following third 
molar surgery from a split-mouth study, concomitantly 
evaluating the preemptive analgesic effect of etoricoxib 
and ibuprofen.
Khan et al. (7) conducted a similar clinical study that 
used the same surgical procedures and collected gingi-
val specimen in patients underwent third molar surgery 
without preoperative administration of NSAIDs aiming 
to evaluate COX expression in oral tissues without the 
use of medication. The aforementioned study showed 
a gradual increase in COX-2 expression at 30, 60, and 
120 minutes after surgery, which is expected for those 
patients that did not intake any NSAIDs. For COX-1, 
however, there was a slight drop at 30 minutes and a 
significant reduction at 60 minutes, but by 120 minutes, 
the COX-1 expression returned to initial levels.  Howe-
ver, it is difficult to make any comparisons between 
their study and the present one because each temporal 
analysis was carried out with a different patient. In other 
words, no single patient was subsequently analyzed at 
three times so that there is no way of knowing whether 
the data would have maintained the same pattern had 
it been registered for a single patient on all occasions. 
In comparison with the present study design, there were 
no medications investigated in a previous gene expres-
sion study (7). If there is a potential change in COX ex-
pression-related parameters following an inflammatory 
process such as dentoalveolar surgeries, these data could 
be properly evaluated in third molar studies involving 
NSAIDs as presently performed. In the present investi-
gation, COX-1 levels in the placebo group did not differ 
between T0 and T30, differing from Khan et al. (7) that 
observed a slight COX-1 level decrease in the studied 
groups. In the ibuprofen and etoricoxib groups, howe-
ver, there was a slight increase that is believed by the use 
of those drugs as the reduction in COX-2 could lead to 
compensatory expression of COX-1.
No significant differences were detected in the COX-2/
COX-1 ratio among the three studied groups. That can 
be explained by cascade compensations and the selec-
tivity of the medications. A high level of COX-1 and 
COX-2 was observed in the placebo group, whereas in 
the etoricoxib and ibuprofen groups due to the reduction 
in COX-2 expression and the increase in COX-1 expres-
sion, there were no observable differences in the COX2/
COX1 ratios. That compensatory behavior shows that 
even non-selective drugs can have satisfactory analgesic 
and anti-inflammatory effects (17), which is supported 
by our findings since the Pearson correlation showed a 
statistically significant difference in the experimental 
groups. Ibuprofen group showed an opposite correla-
tion between specific pain peaks and gene expression of 
both COXs, an opposite relationship between maximum 
mouth opening and COX-1 expression, and a direct co-
rrelation between COX-2 expression and rescue medi-
cation intake. Etoricoxib group showed an opposite co-
rrelation between the COX-1 gingival level and specific 
pain peaks and a direct correlation between COX-2 level 
and determined pain scores.
In third molar studies evaluating gene expression 
of COXs along with the preemptive use of NSAIDs 
(19,20), it is possible to observe results that corrobora-
te with the present findings regarding the temporal ex-
pression of COXs. Lee et al. (19) showed a COX-1 ex-
pression decrease (36%) after 2 and 4h postoperatively, 
and a significant COX-2 expression increase (300%). 
The test groups (ibuprofen and rofecoxib) had a signifi-
cant increase in COX-2 when compared to the placebo 
group. In addition, these authors showed a significant 
relationship between gene polymorphism variability and 
patient pain relief after the use of NSAIDs. In the study 
performed by Lee et al. (20), ketorolac decreased COX-
1 gene expression at the 24-h postoperative evaluation 
and suppressed TBX2. Also, PGE2-related COX-2 ex-
pression remained high even in the 3-h and 24-h periods. 
These findings showed that the effect of COX-selective 
inhibitors on PGE2 levels contribute to inflammatory 
pain relief after third molar surgery, which may support 
the present results.
Conclusions
The present preemptive analgesia study concludes that 
that COX-2 RNAm induction was directly linked to 
third molar-related tissue inflammation and that the rela-
tion between COX-1 and COX-2 levels were inversely 
proportional to the preemptively administered NSAID 
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COX-2selectivity. Clinically, COX-1 and COX-2 gene 
expressions were correlated with third molar-related in-
flammatory events, notably the pain parameters. 
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